View all cases
UPC APP 3053/2025
Jan 21, 2025·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- StatusCase ClosedActionGenericCategoryOther procedural
- Parties
- Division
- Hamburg LD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- English
- EPO Opposition
- Samsung Bioepis NL B.V.Withdrawn2024-05-02
- Amgen Technology (Ireland) Unlimited CompanyWithdrawn2024-10-28
- Salute HC Ilaç Pazarlama A.S.Admissible2025-01-31
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Hamburg LD | Locked |
| Judge Sabine Klepsch | Locked |
| Judge Alima Zana | Locked |
| Judge Stefan Schilling | Locked |
| Judge Rudi Goedeweeck | Locked |
At the UPC: Amgen Group (19 cases)·AstraZeneca Group (13 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patent8 other defendants litigating the same or a related patent
UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 642/2024·UPC CoA 402/2024 and 3 more
Start a free trial to see how each one ended.
More cases: Hamburg LD·2025
Documents
| Document title | Date | Public |
|---|---|---|
| Case closed | 2025-12-05 | Not public |
| Order | 2025-12-02 | Not public |
| Order | 2025-12-02 | Not public |
| Cover sheet | 2025-11-26 | Not public |
| Further pleadings | 2025-11-26 | Not public |
| Receipt | 2025-11-26 | Not public |
| Cover sheet | 2025-11-25 | Not public |
| Application document Claimant | 2025-11-25 | Not public |
| Receipt | 2025-11-25 | Not public |
| Order | 2025-11-18 | Not public |
| Order | 2025-11-18 | Not public |
| Application document Defendant | 2025-11-13 | Not public |
| Other document Defendant | 2025-11-13 | Not public |
| Cover sheet | 2025-11-13 | Not public |
| Other document Defendant | 2025-11-13 | Not public |
| Other document Defendant | 2025-11-13 | Not public |
| Other document Defendant | 2025-11-13 | Not public |
| Other document Defendant | 2025-11-13 | Not public |
| Receipt | 2025-11-13 | Not public |
| Order | 2025-10-21 | Not public |
| Order | 2025-10-21 | Not public |
| Communication | 2025-10-20 | Not public |
| Application | 2025-10-16 | Not public |
| Other document | 2025-10-16 | Not public |
| Cover sheet | 2025-10-16 | Not public |
| Other document | 2025-10-16 | Not public |
| Receipt | 2025-10-16 | Not public |
| Order | 2025-10-08 | Not public |
| Order | 2025-10-08 | Not public |
| Application | 2025-10-02 | Not public |
| Application | 2025-10-02 | Not public |
| Cover sheet | 2025-10-02 | Not public |
| Other document | 2025-10-02 | Not public |
| Receipt | 2025-10-02 | Not public |
| Outcome of the Order | 2025-09-17 | Not public |
| rectification | 2025-09-17 | Not public |
| Outcome of the Order | 2025-09-10 | Not public |
| Deadline extension | 2025-09-10 | Not public |
| Receipt | 2025-09-10 | Not public |
| Receipt | 2025-09-10 | Not public |
| Receipt | 2025-09-10 | Not public |
| 262.2 Application | 2025-09-09 | Not public |
| Deadline extension request | 2025-09-09 | Not public |
| Deadline extension request | 2025-09-09 | Not public |
| Application_for_rectification_ORD_35478_2025 | 2025-09-09 | Not public |
| Anhoerung | 2025-09-04 | Not public |
| Outcome of the Order | 2025-09-04 | Not public |
| Order with grounds | 2025-09-04 | Not public |
| Order with grounds | 2025-09-04 | Not public |
| Order with grounds | 2025-09-04 | Not public |
| Order with grounds | 2025-09-04 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| 20250903_Second_Instance_Costs_Confidentiality_Reply_Amgen signed | 2025-09-03 | Not public |
| Anhoerung | 2025-08-31 | Not public |
| Comments | 2025-08-28 | Not public |
| Anhoerung | 2025-08-25 | Not public |
| Receipt | 2025-08-21 | Not public |
| 20250820_Confidentiality_Applications_262_2_262_A_Second_Instance_costs_Amgen signed | 2025-08-20 | Not public |
| 20250820_Confidentiality_Applications_262_2_262_A_Second_Instance_costs_Amgen signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| 20250820_Second_Instance_Costs_Reply_Amgen_3053_2025_Confidential signed | 2025-08-20 | Not public |
| Exhibit_BP_KF01_Amgen_3053_2025 | 2025-08-20 | Not public |
| Anhoerung | 2025-08-06 | Not public |
| Comments | 2025-07-14 | Not public |
| Anhoerung | 2025-07-02 | Not public |
| Receipt | 2025-01-21 | Not public |
| Application | 2025-01-20 | Not public |